Infections with oncogenic types of HPV cause virtually all cases of cervical cancer worldwide. Prophylactic and or combined prophylactic and early therapeutic types of vaccination against HPV 16, the most important HPV type, could protect against a majority of the cases of cervical cancer globally. Two vaccines are under study. The immunogenicity and safety of HPV 16 virus-like particles as antigens are being evaluated in collaborative Phase 1 and Phase 2 trials at Johns Hopkins. Immunogenicity and safety of the prophylactic vaccine have been demonstrated in work to date. Early trials of a mixed prophylactic/therapeutic vaccine are underway. A full-scale Phase 3 randomized controlled trial of the two vaccines will be fielded soon. Costa Rica was chosen for the Phase 3 trial because of our extensive successful scientific collaborations there, the continued high risk of cervical cancer, the universal medical system providing national linkage, and the likelihood of very high participation over the many needed years of close clinical follow-up. Over 10,000 women will be vaccinated according to current plans. In support of the vaccine trials, a variety of methodologic and ancillary projects are underway or planned, that will maximize the yield of the main effort.

Agency
National Institute of Health (NIH)
Institute
Division of Cancer Epidemiology And Genetics (NCI)
Type
Intramural Research (Z01)
Project #
1Z01CP010177-02
Application #
6755684
Study Section
(EBP)
Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Cancer Epidemiology and Genetics
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Lowy, Douglas R; Herrero, Rolando; Hildesheim, Allan et al. (2015) Primary endpoints for future prophylactic human papillomavirus vaccine trials: towards infection and immunobridging. Lancet Oncol 16:e226-33
Hildesheim, Allan; Wacholder, Sholom; Catteau, Gregory et al. (2014) Efficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial. Vaccine 32:5087-97
Herrero, Rolando; Wacholder, Sholom; Rodríguez, Ana C et al. (2011) Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discov 1:408-19
Baker, Rosalyn; Dauner, Joseph G; Rodriguez, Ana Cecilia et al. (2011) Increased plasma levels of adipokines and inflammatory markers in older women with persistent HPV infection. Cytokine 53:282-5
Herrero, Rolando; Hildesheim, Allan; Rodriguez, Ana C et al. (2008) Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica. Vaccine 26:4795-808
Garcia-Pineres, Alfonso J; Hildesheim, Allan; Trivett, Matthew et al. (2006) Role of DC-SIGN in the activation of dendritic cells by HPV-16 L1 virus-like particle vaccine. Eur J Immunol 36:437-45